ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Novel 10-Protein Score for Liver Fat Content Predicts Cardiovascular-Kidney-Metabolic Disease Risk.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma proteomic signatures predict incident benign prostatic hyperplasia: a prospective cohort study of 20 996 men.Journal of global health · 2026Article
- Cardiovascular-Kidney-Metabolic (CKM) Syndrome Staging and Relevance to Precision Nutrition.Nutrients · 2026Review
- A Novel 10-Protein Score for Liver Fat Content Predicts Cardiovascular-Kidney-Metabolic Disease Risk.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Liver fat content (LFC) is a key biomarker for cardiovascular-kidney-metabolic (CKM), yet noninvasive assessment remains challenging. It aims to develop a plasma proteomic-based LFC score to predict MRI-derived proton density fat fraction (MRI-PDFF), evaluate its association with 14 CKM diseases, and explore interactions with polygenic risk scores (PRS). Both the comprehensive 62-protein and simplified 10-protein LFC scores are developed and validated in 5,320 UK Biobank participants (96.8% White). The 10-protein LFC score, comprising proteins involved in adipogenesis, lipid metabolism, and insulin signaling (IGFBP2, FABP4, MET, CPM, CES1, IGFBP1, CDHR2, RBP5, ERBB2, SSC5D), showed superior diagnostic accuracy for hepatic steatosis compared to fatty liver index(FLI) (AUC = 0.850 vs. 0.794). Among 45,444 participants, it exhibited significant associations with 16 cardiometabolic risk markers and 13 incident CKM outcomes, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes (T2D), chronic kidney disease, and coronary heart disease. The score significantly enhanced risk prediction for 8-10 CKM outcomes beyond standard risk factors and FLI (e.g., MASLD,C-index improved from 0.743 to 0.774; T2D, from 0.773 to 0.806). The score showed significant interactions with PRS for T2D (P-interaction<0.001). The 62-protein model yielded similar results. A 10-protein score accurately quantifies liver fat, predicts cardiometabolic risk, and integrates with genetic risk for precision prevention, providing a practical MRI alternative.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.